1. Khan AS, Rai ME, Gandapur PA, Shah AH, Hussain AA, Siddiq M. Epidemiological risk factors and composition of urinary stones in Riyadh Saudi Arabia. J Ayub Med Coll Abbottabad 2004; 16(3): 56-8. 2. Pourmand Gh, Pourmand B. Epidemiology of stone disease in Iran. Urolithiasis 2012; 85-7. 3. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010; 12(2-3): e86. 4. Stechman MJ, Loh NY, Thakker RV. Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol 2009; 24(12): 2321-32. 5. Safarinejad MR. Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. Urol Res 2007; 35(2): 73–82. 6. Ozbek E. Induction of oxidative stress in kidney. Int J nephrol 2012; 2012: 465897. 7. Tamadon MR, Nassaji M, Ghorbani R. Cigarette Smoking and Nephrolitiasis in Adult Individuals. Nephrourol Mon 2013; 5(1): 702-5. 8. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408(6809): 239‐47. 9. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004; 58(1): 39-4612. 10. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84(21-22): 705‐12. 11. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative Stress and Antioxidant Defense. World Allergy Organ J 2012; 5(1): 9-19. 12. Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, et al. Identification of a novel stress‐ responsive gene Hi95 involved in regulation of cell viability. Oncogene 2002; 21(39): 6017-6031. 13. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53‐regulated sestrins, homologs of bacterial AhpD. Science 2004; 304 (5670): 596-600. 14. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, Mouchel PL, et al. Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 2009; 8(10): 1571–6. 15. Peeters H, Debeer P, Bairoch A, Wilquet V, Huysmans C, Parthoens E, et al. PA26 is a candidate gene for heterotaxia in humans: Identification of a novel PA26-related gene family in human and mouse. Hum Genet 2003; 112(5-6): 573-80. 16. Yang Y, Cuevas S, Yang S, Villar VA, Escano C, Asico L, et al. Sestrin2 Decreases Renal Oxidative Stress, Lowers Blood Pressure, and Mediates Dopamine D2 Receptor–Induced Inhibition of Reactive Oxygen Species Production. Hypertension 2014; 64(4): 825-32. 17. Kuersten S, Goodwin EB. The power of the 3'UTR: translational control and development. Nature 2003; 4(8): 626-37. 18. Jahangirizade K, Nasiri M, Asmarian NS. Association of rs1042658 Polymorphism of the CSF3 Gene with the Susceptibility of Recurrent Pregnancy Loss in Women of Fars Province. Arak Med Uni J 2016; 19(106): 23-31. 19. Li CY, Deng YL, Sun BH. Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis. Urol Res 2009; 37(4): 211-20. 20. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004; 8(2): 75-88. 21. Essler S, Dehne N, Brüne B. Role of sestrin2 in peroxide signaling in macrophages. FEBS Lett 2009; 583(21): 3531–5. 22. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009; 4(4): 804-11. 23. Zhou D, Zhan C, Zhong Q, Li S. Upregulation of sestrin-2 expression via P53 protects against 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity. J Mol Neurosci 2013; 51(3): 967-75. 24. Oberley TD, Verwiebe E, Zhong W, Kang SW, Rhee SG. Localization of the thioredoxin system in normal rat kidney. Free Radic Biol Med 2001; 30(4): 412-24. 25. Simzar S, Ellyin R, Shau H, Sarafian TA. Contrasting antioxidant and cytotoxic effects of peroxiredoxin I and II in PC12 and NIH3T3 cells. Neurochem Res 2000; 25(12): 1613-21. 26. Ichimiya S, Davis JG, O'Rourke DM, Katsumata M, Greene MI. Urine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. DNA Cell Biol 1997; 16(3): 311-21. 27. Yao J, Taylor M, Davey F, Ren Y, Aiton J, Coote P, et al. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 2007; 35(2): 377-82. 28. Hattori F, Murayama N, Noshita T, Oikawa S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 2003; 86(4): 860-8. 29. Boulos S, Meloni BP, Arthur PG, Bojarski C, Knuckey NW. Peroxiredoxin 2 overexpression protects cortical neuronal cultures from ischemic and oxidative injury but not glutamate excitotoxicity, whereas Cu/Zn superoxide dismutase 1 overexpression protects only against oxidative injury. J Neurosci Res 2007; 85(14): 3089-97. 30. Wu CL, Su TC, Chang CC, Kor CT, Chang CH, Yang TH, et al. Tubular Peroxiredoxin 3 as a Predictor of Renal Recovery from Acute Tubular Necrosis in Patients with Chronic Kidney Disease. Sci Rep 2017; 7: 43589. 31. Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 2001; 52(1–2): 35-41. 32. Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 2008; 11(4): 476–87. 33. Soriano FX, Papadia S, Bell KF, Hardingham GE. Role of histone acetylation in the activity-dependent regulation of sulfiredoxin and sestrin 2. Epigenetics 2009; 4(3): 152-8. 34. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128(4): 693–705.
|